Immunotherapy News and Research

Latest Immunotherapy News and Research

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

ACAAI issues updated guidelines for treating stinging insect hypersensitivity

Spring and summer bring bees, wasps, hornets and yellow jackets and, this year, updated advice for those who are allergic to these pesky stinging insects. More than half a million people go to emergency rooms and at least 50 die each year from insect stings.

9 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

European hematologists raise alarm on insufficient research money for blood disorders

European hematologists raise the alarm on the insufficient research money for blood disorders. "Blood cancers kill over 95,000 in the EU every year; the EU must be made aware that more research funds are needed", states Professor Robin Foa, President of the European Hematology Association (EHA) at their annual congress in London.

8 Jun 2011

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy.

8 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Generex not to proceed with acquisition of interest in Global Medical Direct

Generex Biotechnology Corporation today announced that the Company, together with Global Medical Direct, Inc. and its stockholders, have mutually decided not to proceed with the Company's previously announced acquisition of a 51% interest in GMD.

6 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

ACAAI issues updated guidelines for treating stinging insect hypersensitivity

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

European hematologists raise alarm on insufficient research money for blood disorders

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

Generex not to proceed with acquisition of interest in Global Medical Direct

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Cancer vaccine shows improved response rate in patients

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in